Research output per year
Research output per year
Personal profile
Research interests
- Pathogenesis and (immuno)therapy of B cell malignancies.
Specialisation
Hematology/internal medicine
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prof. Anton Hagenbeek 1948-2021: Father of MRD and Lymphoma Expert
Löwenberg, B., Kersten, M. J., Gale, R. P. & van Oers, M., 1 Sep 2021, In: Leukemia. 35, 9, p. 2725-2726 2 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Professor Anton Hagenbeek 1948–2021: Father of MRD and lymphoma expert
Löwenberg, B., Kersten, M. J., Gale, R. P. & van Oers, M., 1 Aug 2021, In: Bone marrow transplantation. 56, 8, p. 2038-2039 2 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study
Saberi Hosnijeh, F., van der Straten, L., Kater, A. P., van Oers, M. H. J., Posthuma, W. F. M., Chamuleau, M. E. D., Bellido, M., Doorduijn, J. K., van Gelder, M., Hoogendoorn, M., de Boer, F., te Raa, G. D., Kerst, J. M., Marijt, E. W. A., Raymakers, R. A. P., Koene, H. R., Schaafsma, M. R., Dobber, J. A., Tonino, S. H., Kersting, S. S., & 2 others, Sep 2020, In: Experimental hematology. 89, p. 55-60.e6Research output: Contribution to journal › Article › Academic › peer-review
Open Access2 Citations (Scopus) -
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia
Leeksma, A. C., Taylor, J., Wu, B., Gardner, J. R., He, J., Nahas, M., Gonen, M., Alemayehu, W. G., te Raa, D., Walther, T., Hüllein, J., Dietrich, S., Claus, R., de Boer, F., de Heer, K., Dubois, J., Dampmann, M., Dürig, J., van Oers, M. H. J., Geisler, C. H., & 11 others, Feb 2019, In: Leukemia. 33, 2, p. 390-402 13 p.Research output: Contribution to journal › Article › Academic › peer-review
35 Citations (Scopus) -
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia
HOVON CLL study group, 1 Jan 2019, In: Haematologica. 104, 1, p. 147-154 8 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access9 Citations (Scopus)